Direxion S&P Biotech Bull 3X

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

US Clinics Race to Enroll Patients in Revolution Medicines Pancreatic Cancer Drug Early Access Plan After FDA Approval

Apellis Pharma released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 268.3 M (forecast USD 203.29 M), actual EPS USD 0.1461 (forecast USD -0.3526)

Revolution Medicines released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 0 (forecast USD 2.425 M), actual EPS USD -2.2908 (forecast USD -1.8344)

Revolution Medicines Submits NDA for Daraxonrasib

Revolution Medicines reports Q1 operating loss of $445.222 million

TG Therap released FY2026 Q1 earnings on May 6 During-Market (EST), actual revenue USD 204.92 M (forecast USD 201.21 M), actual EPS USD 0.1199 (forecast USD 0.2719)

Revolution Medicines Exec Exercised Stock Options and Sold Shares

Revolution Medicines to release FY2026 Q1 earnings on May 6 After-Market EST, forecast revenue USD 2.425 M, EPS USD -1.8392

TG Therap to Release FY2026 Q1 Earnings on May 6 During Market Hours (EST), Forecast Revenue USD 200.92 M, EPS USD 0.2719

Revolution Medicines Sues Erasca for Patent Infringement, Stock Rises

Mizuho Maintains Buy Rating on Revolution Medicines, Targeting $185

Revolution Medicines Releases RM-055 Preclinical Data

Revolution Medicines Publishes Clinical Data for Daraxonrasib in Treating Pancreatic Cancer

Revolution Medicines issues $250 million convertible senior notes

Revolution Medicines' daraxonrasib shows positive results in pancreatic cancer phase III trial

Biogen plans to acquire Apellis

Tema Etfs LLC Reduced Holdings in Revolution Medicines, Inc.

Biogen to acquire Apellis Pharmaceuticals for $41 per share

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

RenovoRx Earnings Call Signals Commercial Inflection

RNXT

ARKG

LABU

SBIO

RenovoRx, Inc. reported record Q1 2026 revenue of $563,000, marking a 136% sequential growth. The company highlighted strong gross margins of 85.1% and an expanding commercial footprint with 16 active cancer centers. A pivotal Phase III trial is nearing full enrollment, and recent financing extends its cash runway into 2027. Despite impressive growth, management acknowledged execution risks and the need for consistent center conversions to sustain revenue growth. The company maintains a full-year revenue outlook of $3.0 million to $4.0 million.

Tip Ranks

RenovoRx

SPDR S&P Health Equip

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

ALPS Medical Breakthrough

iShares Biotechnology ETF

VG Health

Health Care Select Sector SPDR

iShares US Medical Devices

VanEck Biotech ETF

IMNN

IBBQ

Imunon, Inc. held its Q1 earnings call, highlighting clinical advancements with IMNN-001, which shows promising survival data. However, management expressed concerns over rising cash burn and capital market challenges. The pivotal OVATION III trial is underway, with a focus on minimizing shareholder dilution through strategic financing. Despite strong investigator interest, the lengthy timeline for data and regulatory submission poses risks for investors. The company aims to present detailed efficacy data at an upcoming R&D Day in 2026.

Imunon

Invesco Nasdaq Biotechnology ETF

Imunon Earnings Call Balances Breakthroughs and Cash Strain

CBUS

Cibus, Inc. reported its Q1 earnings, raising $37 million to extend its cash runway to late Q1 2027. The company noted improved cost control, with operating expenses down nearly $8 million, but acknowledged ongoing financial risks and uncertainty in revenue generation. Key developments include progress in its rice program in LATAM and advancements in sustainable ingredients. However, the U.S. rice launch has been delayed to 2029, and profitability remains distant with a net loss of $21.2 million.

Cibus

Cibus Earnings Call: Cash Extended, Execution Critical

588130

159892

510660

Antengene has appointed Bing Hou as chief scientific officer, effective May 19, 2026. He will oversee drug discovery and R&D efforts, reporting to CEO Jay Mei. Hou, who joined Antengene in 2019, previously served as vice president of discovery science. He holds a PhD in biomedicine and has over 40 patent applications.

PUBT

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

E Fund CSI 300 Health Care ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

BlackRock, Inc.

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

ANTENGENE-B

Antengene appoints Bing Hou as chief scientific officer

Antengene Corporation has appointed Dr. Bing Hou as Chief Scientific Officer to enhance its R&D strategy and advance its next-generation therapeutic pipeline. Dr. Hou, who has been with Antengene since 2019, will lead efforts in Drug Discovery and Translational Medicine. His leadership is expected to strengthen the company's proprietary platforms, including the AnTenGager® T-cell engager platform, and support the development of innovative therapies for autoimmune diseases and cancers.

PR Newswire

ChinaAMC CSI Biotechnology Theme ETF

Proshares UltraShort Nasdaq Biotech

UCB S.A.

Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline

BBIO

BridgeBio Pharma received a Hold rating and price target from Citi analyst today.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In addition to Citi, BridgeBio Pharma also received a Hold from J.P. Morgan’s Eric Joseph in a report issued today. However, on May 13, Bank of America Securities reiterated a Buy rating on BridgeBio Pharma (NASDAQ: BBIO).

Bridgebio Pharma

Direxion S&P Biotech Bear 3X

Citigroup

JPMorgan Chase

Bank of America

CITIGROUP INC 6.250 NON CUM SER II PFD WI

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

BridgeBio Pharma (BBIO) Gets a Hold from Citi

ERAS

RVMD

Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (NASDAQ:ERAS) regarding possible violations of federal securities laws following a patent infringement allegation from Revolution Medicines. This news caused Erasca's stock to drop by approximately 48%. No lawsuit has been filed yet, and the investigation is ongoing. Investors with information or interest are encouraged to contact the law firm.

MorningStar

Erasca

Revolution Medicines

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.

EXEL

Exelixis EVP and CFO Christopher J. Senner disposed of 75,793 shares for $3.78 million on May 15 and May 18. He withheld 40,892 shares at $51.1 for taxes related to RSU vesting and sold 34,901 shares at an average price of $50. Following these transactions, his directly held shares decreased to 952,317, with an additional 2,723 shares held indirectly through a 401(k) plan.

Exelixis

Exelixis EVP, CFO Christopher Senner disposes 75,793 shares for $3.78 million

VXRT

Vaxart (VXRT) has urged shareholders to support its board nominees amid a proxy contest, emphasizing the importance of experienced leadership for its oral vaccine platform. The company reported progress in its COVID-19 trial and other vaccine programs, while detailing financial measures to extend its cash runway. Analysts rate VXRT as a Buy with a $4.00 price target, though execution risks remain. Vaxart focuses on developing oral vaccines for infectious diseases, positioning itself against traditional injectable products.

Vaxart

Dynavax Tech

Vaxart Urges Shareholder Support Amid Proxy Contest, Updates Pipeline

PHVS

Pharvaris Chief Commercial Officer Wim Souverijns sold 10,000 shares on May 15 for $299,163 at a weighted average price of $29.92. Following the transaction, he holds 45,111 shares.

Pharvaris BV

Pharvaris Chief Commercial Officer Wim Souverijns sells 10,000 shares for $299,163

OCGN

Ocugen Inc. (OCGN) shares fell 2.99% to $1.30 on Tuesday, marking the fourth consecutive day of losses. The stock is now 52.29% below its 52-week high of $2.73 reached on March 17. The broader market also declined, with the S&P 500 down 0.67% and the Dow Jones down 0.65%. Trading volume was 5.5 million, below the 50-day average of 9.4 million.

Direxion S&P Biotech Bull 3X(LABU.US)